COMPARE-ACUTE: FFR-Guided Non-Culprit Vessel Revascularization in Primary Angioplasty

Courtesy of the SBHCI.

COMPARE-ACUTE: FFR-Guided Non-Culprit Vessel Revascularization in Primary AngioplastyAbout 50% of patients admitted with acute ST-segment elevation myocardial infarction also present lesions in another vessel. Whether to treat these or not, and the optimal moment to treat non-culprit infarction-related vessels are still controversial issues.

 

The COMPARE-ACUTE study was recently published and showed that fractional flow reserve (FFR)-guided complete functional revascularization is superior to revascularization of the culprit artery alone. Now, we have a cost analysis of this strategy.

 

The analysis included patients with acute ST-segment elevation myocardial infarction who underwent primary angioplasty. A segment was randomized to receive FFR-guided complete revascularization (n = 295) and the other was assigned to receive culprit artery treatment only (n = 590).

 

All non-culprit artery lesions over 50% were analyzed through FFR in all patients. In patients randomized to complete revascularization, the operator was informed of the result of the FFR; however, if the patient belonged to the control group, FFR results were blinded.

 

Complete revascularization could be performed during the index procedure or within 72 hours from primary angioplasty, if there were clinical reasons for postponement.

 

The combined endpoint of all-cause death, infarction, stroke, or any revascularization at 12 months took place in 7.8% of patients who received FFR-guided complete revascularization vs. 20.5% of patients in the control group (p < 0.001). The difference was basically driven by the rate of repeat revascularization (6.1% vs. 17.5%; p < 0.001).

 

In all countries in which the study was carried out, FFR-guided complete revascularization was almost 30% cheaper than treatment of the culprit vessel alone.

 

Conclusion

FFR-guided complete revascularization after primary angioplasty reduced the number of events when compared to treatment of the culprit vessel alone, and it also lowered costs, at least in the countries in which this study took place (United States, Poland, Sweden, Netherlands, and Germany).

 

Courtesy of the (SBHCI).

 

Dr. Elmie Omerovic.
Dr. Elmie Omerovic.

Original title: FFR-Guided Complete Revascularisation During Primary Angioplasty Is Cost-Saving: Results from the COMPARE-ACUTE Trial.

Presenter: Elmie Omerovi.

 

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroCTO: Rechanneling vs. Optimal Medical Treatment in Total Occlusions

Courtesy of the SBHCI. Chronic total occlusions represent around 18% of all coronary lesions. However, they account for just 5% of all interventions, which means...

AIDA: bioresorbable scaffold thrombosis still a concern in studies

Courtesy of the SBHCI. This study presented at PCR and simultaneously published by NEJM still challenges the safety of bioresorbable scaffolds.   This was a multicenter noninferiority...

PRISON IV: DES with resorbable polymer vs. DES with permanent polymer in total occlusions

Courtesy of SBHCI. The PRISON IV trial compared the sirolimus eluting stent with ultra-thin struts and biodegradable polymer vs. the second-generation everolimus-eluting stent with thin...

[SURTAVI] Sub-study of neurological events: more evidence in favor of TAVR

Courtesy of SBHCI. The occurrence of a periprocedural neurological events is associated to an increased risk of death and morbidity at long term, both for...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...